Company News_CGeneTech_small molecular innovative drugs

News Center

Home page

"Golden Duo" DPP-4! The 2025 Edition of the "Chinese Expert Consensus on Triple Antidiabetic Therapy for T2D" is Released!

Recently, the "Chinese Expert Consensus on Optimized Triple Oral Antidiabetic Therapy for Adult Patients with Type 2 Diabetes (2025 Update)"—hereafter referred to as the "Consensus"—was published in the Chinese Journal of Diabetes.

Time：2025-08-28 11:49

Shengshi Taikang Wins "New Glory Decade – Most Innovative" Award

Recently, the 10th Annual Conference of New Drug Founder hosted the "New Yao Shi Year Award Ceremony," where Shengshi Taikang was honored with the "New Yao Shi Year – Most Innovative Company" award, highlighting the company's outstanding achievements in new drug development over the past decade, as well as its significant contributions to the industry's growth.

Time：2025-08-28 11:26

Professor Li Yanbing: From Structural Innovation to Efficacy Validation, Sengliptin Sets a "New Benchmark" for DPP-4 Inhibitor Therapy

DPP-4 inhibitors play a crucial role in the treatment of type 2 diabetes mellitus (T2DM), and to meet diverse clinical needs, they are continuously being refined and upgraded. China’s next-generation, highly selective DPP-4 inhibitor, senglitinib, has pioneered breakthrough innovations in its molecular structure, laying the foundation for even better glycemic control and demonstrating "Best-in-Class" potential. *International Diabetes* has invited Professor Yanbing Li from the First Affiliated Hospital of Sun Yat-sen University to provide an in-depth introduction and analysis of this groundbreaking drug, offering valuable insights to help optimize T2DM treatment strategies.

Time：2025-08-28 10:22

Shengshi Taikang Wins Jiangsu Province's "Double Yellow Egg" for Innovation and Entrepreneurship Talent

As Jiangxiang approaches the Minor Fullness solar term, the warmth stirs the chirping of grasshoppers. Recently, the official results for Jiangsu Province’s 2024 "Double Innovation Plan" were announced. Shengshi Taikang’s talented team has achieved a remarkable "double win": Dr. Wang Tong, Chief Scientific Officer, led her core team to successfully secure their place as a 2024 Jiangsu Provincial "Double Innovation Team"—the only "Innovation Team" in Suzhou’s biopharmaceutical sector—while Dr. Zhao Jiahong, Chief Medical Officer, was also honored as a 2024 Jiangsu Provincial "Double Innovation Talent." Jiangsu Province’s "Double Innovation Plan" focuses primarily on attracting and supporting top-tier talents in critical fields such as cutting-edge, high-precision, and specialized areas, as well as technologies that address key industry bottlenecks. By backing the development of groundbreaking innovations in priority sectors, the program has become a flagship initiative for Jiangsu’s talent strategy. The plan aligns closely with the province’s strategic industrial priorities, playing a vital role in enhancing autonomous innovation capabilities, optimizing industrial structures, and driving rapid economic growth. Dr. Wang Tong, who recently earned the title of Jiangsu Provincial "Double Innovation Talent" last year, has once again led her company’s core team to clinch the prestigious "Double Innovation Team" honor, underscoring the team’s unwavering commitment to continuous innovation. As Shengshi Taikang’s Chief Scientific Officer, Dr. Wang brings over two decades of comprehensive drug R&D and management expertise gained from leading U.S. pharmaceutical companies and research institutions. She is a visionary scientist capable of breaking through technological barriers, pioneering emerging disciplines, and propelling advancements in the pharmaceutical industry. Since joining Shengshi Taikang, she has earned recognition as a science and technology leader at multiple levels, bringing fresh, innovative thinking and cutting-edge methodologies to the company. Under her guidance, the company has established a robust, integrated platform for new drug development and commercialization, accelerating the advancement of its pipeline. Notably, the company’s lead product candidate—a novel class-II antidiabetic drug called Sengledipine—has already hit the market. Meanwhile, another key member of the "Double Innovation Team," Dr. Zhao Jiahong, has also been recognized as a Jiangsu Provincial "Double Innovation Talent." As Shengshi Taikang’s Chief Medical Officer, Dr. Zhao boasts more than 20 years of hands-on experience in clinical drug trials and team management, and serves as an external expert for the CDE (Center for Drug Evaluation). With extensive practical knowledge in medical affairs, early-stage drug development, clinical development strategies, and international multi-center clinical trials, he has spearheaded or contributed to over 600 clinical projects. He also possesses deep insights into post-marketing drug reevaluation processes. Since joining Shengshi Taikang, Dr. Zhao has taken full responsibility for overseeing the company’s critical workstreams, including new drug clinical development strategies, pathways, and post-market expansion studies. Among the team’s standout members is Dr. Lu Qin, who holds an associate senior professional title and graduated from Fudan University with a specialization in medical systems biology. A prolific researcher in the life sciences, Dr. Qin has published numerous high-quality papers and secured nearly 10 authorized invention patents. She has led her company’s bio-team to successfully tackle several challenging projects, earning accolades such as the Park’s Leading Talent Award. Dr. Ou Yang Zhenwu, meanwhile, graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, with a focus on organic chemistry. Renowned for his exceptional academic and professional achievements in medicinal chemistry, Dr. Ou has authored six influential papers in internationally acclaimed chemical journals, showcasing his profound expertise in chemical synthesis and drug design. Since joining the company, Dr. Ou has repeatedly applied innovative synthetic methodologies to streamline complex drug discovery processes, significantly boosting screening efficiency while simultaneously reducing development costs—a testament to his invaluable contributions to the company’s ongoing efforts in new drug innovation. Shengshi Taikang, powered by this dynamic team of innovators, is a biotech enterprise currently in the commercialization phase. Its seasoned leadership team boasts decades of global experience across the entire lifecycle of pharmaceutical products, dedicated to advancing the research, development, and industrialization of high-quality, differentiated small-molecule innovative drugs. Leveraging an integrated drug R&D technology platform and a forward-thinking, diversified business perspective, the company has built a robust pipeline spanning therapeutic areas such as diabetes, cancer, and autoimmune diseases—each offering unique value propositions in the competitive landscape of modern medicine.

Time：2025-05-22 19:05

Media Spotlight | Yu Qiang, the "Not-So-Smart" Entrepreneur Behind Senglitin, His Diabetes Drug

Yu Qiang, founder and CEO of Shengshi Taikang, a chemist with a PhD from Peking University, founded a biotech company in the U.S. in the early 2000s before returning to China to establish Shengshi Taikang. Under his leadership, the company has developed a new drug for type 2 diabetes—the next-generation DPP-4 inhibitor sengliflozin—which has now been approved for market launch.

Time：2025-04-16 13:53

Media Focus | Professor Su Qing: Grounded in the Present, Empowered by Innovation—Senglitin Ushers in a New Era of DPP-4 Inhibitor Therapy

In recent years, the prevalence of diabetes in China has continued to rise steadily, yet control rates remain disappointingly low, underscoring the urgent need for more effective prevention and management strategies, as well as optimized treatment approaches. Against this backdrop, a new-generation DPP-4 inhibitor—sengliflozin—has been approved for use in China, offering a fresh therapeutic option for patients with T2DM. To gain a deeper understanding of the current state of diabetes incidence and management in China, as well as the critical role of DPP-4 inhibitors in blood sugar control—particularly the unique features and impressive glucose-lowering efficacy of the latest DPP-4 inhibitor, sengliflozin—we are pleased to invite Professor Qing Su from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an in-depth interview. She will share her expert insights and invaluable experience on this vital topic.

Time：2025-04-15 13:45

New Update | Shengshi Taikang Honored with BIOCHINA Awards’ "2024 Innovation Breakthrough Enterprise" Award

Recently, at the BIOCHINA E-Trade Bio-Industry Conference, the organizers unveiled the BIOCHINA Awards 2024 list of corporate honors. Shengshi Taikang was awarded the "Innovation Breakthrough Enterprise" prize in recognition of its outstanding achievements in the innovative pharmaceutical sector.

Time：2025-03-19 11:33

Clinical Story | Professor Junhang Tian: The "Truth, Goodness, and Beauty" of Clinical Trials

At the Third People's Hospital of Luoyang, treatment and research on endocrine and metabolic diseases are in full swing. As an expert in this field, Professor Tian Junhang boasts extensive experience in clinical drug studies focused on metabolic disorders. Recently, the Clinical Research Promotion Public Welfare Fund was honored to conduct an exclusive interview with Professor Tian. He shares his unique perspective on the "truth, goodness, and beauty" principles guiding clinical trials, while also emphasizing that the country should take a top-down approach to further refine its healthcare system.

Time：2025-03-11 11:18

< 1 2 3 4...8 >

Contact Information

Address: Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Email: hr@cgenetech.com.cn

Tel： +86-512-62956960（Recruitment）

+86-512-62956961（marketing）

SEO tags

中企跨境-全域组件制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地